Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial

Antonio J. Vallejo-Vaz; Rana Fayyad; S. Matthijs Boekholdt; G. Kees Hovingh; John J. Kastelein; Shari Melamed; Philip Barter; David D. Waters; Kausik K. Ray

doi:https://doi.org/10.1161/CIRCULATIONAHA.117.032318

Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial

Antonio J. Vallejo-Vaz, Rana Fayyad, S. Matthijs Boekholdt, G. Kees Hovingh, John J. Kastelein, Shari Melamed, Philip Barter, David D. Waters, Kausik K. Ray

Research output: Contribution to journal › Article › Academic › peer-review

133 Citations (Scopus)

Abstract

BACKGROUND: Mendelian randomization data suggest that the genetic determinants of lifetime higher triglyceride-rich lipoprotein-cholesterol (TRL-C) are causally related to cardiovascular disease and therefore a potential therapeutic target. The relevance of TRL-C among patients receiving statins is unknown. We assessed the relationship between TRL-C and cardiovascular risk, and whether this risk was modifiable among patients receiving statins in the TNT trial (Treating to New Targets).

Original language	English
Pages (from-to)	770-781
Journal	Circulation
Volume	138
Issue number	8
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.117.032318
Publication status	Published - 2018

Access to Document

https://doi.org/10.1161/CIRCULATIONAHA.117.032318

Cite this

@article{d0ceb56d4a504dbab6bebec0d8dff2b2,

title = "Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial",

abstract = "BACKGROUND: Mendelian randomization data suggest that the genetic determinants of lifetime higher triglyceride-rich lipoprotein-cholesterol (TRL-C) are causally related to cardiovascular disease and therefore a potential therapeutic target. The relevance of TRL-C among patients receiving statins is unknown. We assessed the relationship between TRL-C and cardiovascular risk, and whether this risk was modifiable among patients receiving statins in the TNT trial (Treating to New Targets).",

author = "Vallejo-Vaz, {Antonio J.} and Rana Fayyad and Boekholdt, {S. Matthijs} and Hovingh, {G. Kees} and Kastelein, {John J.} and Shari Melamed and Philip Barter and Waters, {David D.} and Ray, {Kausik K.}",

year = "2018",

doi = "https://doi.org/10.1161/CIRCULATIONAHA.117.032318",

language = "English",

volume = "138",

pages = "770--781",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "8",

}

TY - JOUR

T1 - Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial

AU - Vallejo-Vaz, Antonio J.

AU - Fayyad, Rana

AU - Boekholdt, S. Matthijs

AU - Hovingh, G. Kees

AU - Kastelein, John J.

AU - Melamed, Shari

AU - Barter, Philip

AU - Waters, David D.

AU - Ray, Kausik K.

PY - 2018

Y1 - 2018

N2 - BACKGROUND: Mendelian randomization data suggest that the genetic determinants of lifetime higher triglyceride-rich lipoprotein-cholesterol (TRL-C) are causally related to cardiovascular disease and therefore a potential therapeutic target. The relevance of TRL-C among patients receiving statins is unknown. We assessed the relationship between TRL-C and cardiovascular risk, and whether this risk was modifiable among patients receiving statins in the TNT trial (Treating to New Targets).

AB - BACKGROUND: Mendelian randomization data suggest that the genetic determinants of lifetime higher triglyceride-rich lipoprotein-cholesterol (TRL-C) are causally related to cardiovascular disease and therefore a potential therapeutic target. The relevance of TRL-C among patients receiving statins is unknown. We assessed the relationship between TRL-C and cardiovascular risk, and whether this risk was modifiable among patients receiving statins in the TNT trial (Treating to New Targets).

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85055023130&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/29618599

U2 - https://doi.org/10.1161/CIRCULATIONAHA.117.032318

DO - https://doi.org/10.1161/CIRCULATIONAHA.117.032318

M3 - Article

C2 - 29618599

SN - 0009-7322

VL - 138

SP - 770

EP - 781

JO - Circulation

JF - Circulation

IS - 8

ER -

Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial

Abstract

Access to Document

Other files and links

Cite this